

## RESPONSE OF FALCIPARUM MALARIA IN VIVO TO CHLOROQUINE IN KUMASI/GHANA

**Acheampong, J.W.** MD, FWACP

**Ohene Adjei.** Dr. rer nat, DTM & P

**Baffoe-Bonnie, B.** MD, FWACP

**Parry, E.H.O.** MD, FRCP  
School of Medical Sciences,  
University of Science & Technology, Kumasi.

### ABSTRACT

In 50 patients, who presented with malaria, the presence of *Plasmodium falciparum* was confirmed in thin and thick blood films. They were treated with a total dose of 25mg/kg chloroquine base. It was noticed that in Kumasi, Ashanti Region:

a) there is a clear evidence of decreased sensitivity of *P. falciparum* to chloroquine.

b) chloroquine is still effective in the treatment of malaria and remains the drug of first choice unless there is history of allergy.

In 30 (60.0%) patients parasitaemia cleared within 3 days. In 18 (36%) patients clearance of parasitaemia was between day 4 and day 8.

c. In 2 (4%) patients there was no absolute clearance although there was a significant reduction of the parasitaemia (resistance of RII type).

The mean clearance time for the 48 patients was 3.72 + 1.52 days.

### KEYWORDS.

Malaria, chloroquine, patient,

### INTRODUCTION

Malaria is still prevalent in Africa. In East, South and Central Africa, the disease is deeply entrenched due to the added problem of *Plasmodium falciparum* strains being resistant to chloroquine.<sup>1,2</sup> There are recent reports of chloroquine resistance in West Africa, in countries such as Cameroon<sup>3</sup> and Benin.<sup>4</sup> In Nigeria, there has been a reported decreased sensitivity of *P. falciparum* to chloroquine<sup>5</sup>. Clinical resistance of *P. falciparum* to chloroquine was reported in Accra, Ghana in 1986.<sup>6</sup> In vivo *P. falciparum* resistance at the RI and RII levels to chloroquine in Accra/Ghana has been confirmed.<sup>7</sup>

In Ghana malaria is generally endemic in all areas, however there is so much interregional as well as inter-district variations in prevalence due to the influence of rainfall, vegetation and human behaviour,<sup>8</sup> that it is very important for each region and district to have adequate information on the in vivo sensitivity of the parasite *P. falciparum* to chloroquine. No reports are available yet on the in vivo susceptibility of *P. falciparum* to chloroquine from Kumasi, hence the importance of this work in an urban area.

### Materials and Methods:

Between June 1988, and December, 1988 study was conducted in Komfo Anokye Teaching Hospital, Kumasi in the Ashanti Region of Ghana. 50 patients presenting with malaria and the presence of *P. falciparum* confirmed microscopically were selected. Patients of both sexes aged between 1 1/2 years and 50 years. Patients with mixed malarial infection, were excluded. Patients who were seriously ill were also excluded. All patients were resident in Kumasi. All patients were given a total of 25mg/kg chloroquine base orally in 3 divided doses on an out-patient basis (10mg/kg on day 0 and 1; 5mg/kg on day 2). Chloroquine was given by one of us and the patients observed for 60 minutes after intake; to ensure that drug was not vomited.

The patients were seen daily until the asexual *P. falciparum* parasites had disappeared in the blood films. Asexual parasites were counted in 100 fields of the thick film using a X 100 oil immersion objective and a X 6 eye

Daily parasitic counts (per 100 fields in 50 patients  
with P. falciparum malaria after treatment with  
chloroquine (25 mg/kg body weight)

No	Age	Sex	D A Y											
			0	1	2	3	4	5	6	7	14	21	28	
1	3½	M	541	501	300	107	35	12	0	0	0	-	-	-
2	19	M	276	140	35	0	0	0	0	0	0	-	-	-
3	56	F	150	84	22	0	0	0	0	0	0	-	-	-
4	3	F	231	101	47	0	0	0	0	0	0	-	-	-
5	31	M	631	530	500	520	486	301	197	200	chloroquine discontinued			
6	50	M	247	138	97	0	0	0	0	0	0	-	-	-
7	7	M	498	301	79	0	0	0	0	0	0	-	-	-
8	14	M	601	581	500	439	402	401	276	262	chloroquine discontinued			
9	15	F	170	56	10	0	0	0	0	0	0	-	-	-
10	21	M	542	401	323	147	98	54	13	0	0	-	-	-
11	7	F	582	479	197	89	0	0	0	0	0	-	-	-
12	7	M	176	48	0	0	0	0	0	0	0	-	-	-
13	16	M	78	16	0	0	0	0	0	0	0	-	-	-
14	36	M	240	200	103	0	0	0	0	0	0	-	-	-
15	34	F	120	89	46	0	0	0	0	0	0	-	-	-
16	9	M	382	383	279	86	42	0	0	0	0	-	-	-
17	22	F	176	43	0	0	0	0	0	0	0	-	-	-
18	32	M	107	34	12	0	0	0	0	0	0	-	-	-
19	13	M	423	137	82	41	0	0	0	0	0	-	-	-
20	11	F	283	107	31	0	0	0	0	0	0	-	-	-
21	11	M	302	273	200	109	0	0	0	0	0	-	-	-
22	6	M	571	321	208	184	149	101	0	0	0	-	-	-
23	19	F	437	201	95	0	0	0	0	0	0	-	-	-
24	25	F	498	301	289	174	63	0	0	0	0	-	-	-
25	37	F	582	376	289	250	98	0	0	0	0	-	-	-

26	11	F	132	97	0	0	0	0	0	0	-	-	-
27	5	M	370	182	46	0	0	0	0	0	-	-	-
28	15	F	406	383	19	0	0	0	0	0	-	-	-
29	27	M	197	63	0	0	0	0	0	0	-	-	-
30	48	M	346	281	39	0	0	0	0	0	-	-	-
31	13	F	384	273	140	0	0	0	0	0	-	-	-
32	29	F	256	136	100	54	12	0	0	0	-	-	-
33	17	M	201	131	89	0	0	0	0	0	-	-	-
34	9	M	348	146	90	49	0	0	0	0	-	-	-
35	5	F	309	141	87	37	0	0	0	0	-	-	-
36	4	M	279	100	0	0	0	0	0	0	-	-	-
37	13	F	355	176	48	0	0	0	0	0	-	-	-
38	1½	M	507	473	296	143	89	16	0	0	-	-	-
39	15	M	421	179	93	0	0	0	0	0	-	-	-
40	4	M	98	13	0	0	0	0	0	0	-	-	-
41	24	F	513	436	241	109	87	9	0	0	-	-	-
42	4	F	691	342	132	69	0	0	0	0	-	-	-
43	8	M	436	218	107	0	0	0	0	0	-	-	-
44	17	M	546	401	383	273	185	67	0	0	-	-	-
45	14	F	396	301	273	189	102	93	88	36	-	-	-
46	13	M	191	167	95	0	0	0	0	0	-	-	-
47	17	F	403	246	98	0	0	0	0	0	-	-	-
48	16	M	521	306	106	0	0	0	0	0	-	-	-
49	18	M	143	75	39	0	0	0	0	0	-	-	-
50	30	F	527	349	239	106	95	43	13	0	-	-	-

piece. The mean parasite clearance time was calculated according to the method used by Midala *et al.* 1988.<sup>5</sup>

## RESULTS

As seen in Table 1, the pretreatment parasitaemia varied between 78 (case No. 13) and 691 (case No. 42) counted in 100 fields of the thick film. 30 (60%) patients became parasite negative during the first 3 days. None of the patients achieved a total clearance of parasitaemia on day 1. 18 (36%) patients (case No. 5 and case No. 8) demonstrated a decreased parasitaemia but did not achieve a total clearance of parasitaemia by day 8. They later received amodiaquine (camoquin) which successfully cleared the parasitaemia.

## DISCUSSION

In 48 (96%) patients, it was found that asexual parasitaemia had disappeared within 8 days. In 2 (4%) patients there was a decrease in parasitaemia but not a total clearance (Resistance type RII). These findings indicate that *P. falciparum* is sensitive to chloroquine in this part of Ghana. However, in 1988 Ofori Adjei *et al.*, found chloroquine resistance in Accra, and we have now demonstrated the emergence of resistance of *P. falciparum* to chloroquine in Central Ghana.

Reports up to 1984 from Ibadan in Southern Nigeria show a complete clearance of parasitaemia within 3 days (Aderounmu *et al.*, 1980; Walker *et al.*, 1984). Midala also reported in Zaria in 1988 that in his study, 82% of the patients were parasite negative within the first 3 days, the remaining 19% needed 4 or 5 days for the parasitaemia to disappear. In our study, 60% of the patients became parasite negative within 3 days, while a large number 36%

of the patients became negative within 8 days with a mean clearance of  $3.72 + 1.52$  days. Reports received from Accra/Ghana showed a mean clearance of  $74.25 + 25.5$  hours ( $3.09 + 1.06$  days) (Ofori Adjei *et al.*, 1988) and from Zaria/Nigeria,  $3.45 + 1.25$  days (Midala *et al.*, 1988).

The mean parasite clearance time is unusually long, our results also suggest the decreased parasite susceptibility of chloroquine in Ghana. The presence of the resistant strain of *P. falciparum* at the RII level also confirms similar observation by Ofori Adjei *et al.*, in Accra, in 1988. Chloroquine, however, is still effective in the treatment of malaria in Kumasi.

## REFERENCES

1. World Health Organisation, (1984). Areas where chloroquine-resistant *Plasmodium falciparum* has been reported. *Weekly Epidemiological Reports*; 59 (31): 238.
2. Isaacson M., Cox G.A., Bac D.J., (1985). Chloroquine-resistant *falciparum* malaria acquired in South Africa. *British Medical Journal*; 290: 1353.
3. Sansonetti P.J., Lebras C., Verdier F., Charmot G., Dupont B., Lapresle C., (1985). Chloroquine-resistant *Plasmodium falciparum* in Cameroon. *Lancet*; i: 1154.
4. Le Bras J., Jatfin I., Bource P., (1986). Chloroquine-resistant *falciparum* malaria in Benin. *Lancet*; ii: 1043-1044.
5. Midala T.A.S., Lege-Oguntoye L., Werbinaka B., Bhatt G.C., (1988). In vivo sensitivity of *Plasmodium falciparum* to chloroquine in Zaria, Nigeria. *Journal of Tropical Medicine and Hygiene*; 91: 9-11.
6. Neequaye J., (1986). In vivo chloroquine-resistant *falciparum* malaria in Western Africa. *Lancet*; i: 153.
7. Ofori Adjei D., Adjepon-Yamoah K.K., Commey J.O.O., Ofori-Adjei E., (1988). In vivo sensitivity of *P. falciparum* to chloroquine in Accra, Ghana. *Ghana Medical Journal*; 22 (1): 11-14.
8. Agadzi V.K., (1986). Malaria in Ghana. *A Bibliographic Review*.